ArticlePLoS neglected tropical diseases2021
An antibody targeting type III secretion system induces broad protection against Salmonella and Shigella infections.
Article in PLoS neglected tropical diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 15 citations in OpenAlex.
- Multifunctional antibody responses from a primateScience translational medicine · 2026Article
- Innovative multi-epitope vaccine engineering for dual protection against Salmonella and Shigella leveraging FliC flagellin protein adjuvant properties: an immunoinformatics-based approach.Journal of translational medicine · 2026Article
- Human antibodies as emerging drugs for antimicrobial resistance.Trends in immunology · 2026Review
- Protective and pathogenic antibody responses from a primate Shigella outbreak inform vaccine design.bioRxiv : the preprint server for biology · 2025Article
- Article
- Neutralizing antibodies induced by IpaB and IpaC mRNA vaccines inhibitMicrobiology spectrum · 2025Article
- Reverse vaccinology-based identification and in silico characterization of immunogenic membrane proteins of Salmonella Typhimurium as novel vaccine targets against multidrug-resistant infections.BMC microbiology · 2025Article
- Epitope mapping via in vitro deep mutational scanning methods and its applications.The Journal of biological chemistry · 2025Review
- Mapping the functional B-cell epitopes ofApplied and environmental microbiology · 2024Article
- Vaccines and Monoclonal Antibodies as Alternative Strategies to Antibiotics to Fight Antimicrobial Resistance.International journal of molecular sciences · 2024Review
- Development of a visual Adhesion/Invasion Inhibition Assay to assess the functionality ofFrontiers in immunology · 2024Article
- Salmonella typhimurium targeting with monoclonal antibodies prevents infection in mice.PLoS neglected tropical diseases · 2023Article
- Functional assays to evaluate antibody-mediated responses againstFrontiers in cellular and infection microbiology · 2023Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Salmonella and Shigella bacteria are food- and waterborne pathogens that are responsible for enteric infections in humans and are still the major cause of morbidity and mortality in the emerging countries. The existence of multiple Salmonella and Shigella serotypes as well as the emergence of strains resistant to antibiotics requires the development of broadly protective therapies. Recently, the needle tip proteins of the type III secretion system of these bacteria were successfully utilized (SipD for Salmonella and IpaD for Shigella) as vaccine immunogens to provide good prophylactic cross-protection in murine models of infections. From these experiments, we have isolated a cross-protective monoclonal antibody directed against a conserved region of both proteins. Its conformational epitope determined by Deep Mutational Scanning is conserved among needle tip proteins of all pathogenic Shigella species and Salmonella serovars, and are well recognized by this antibody. Our study provides the first in vivo experimental evidence of the importance of this common region in the mechanism of virulence of Salmonella and Shigella and opens the way to the development of cross-protective therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.